80% of Patients on Dialysis Struggle to Manage Serum Phosphorous Levels
In a survey conducted by Ardelyx and the National Kidney Foundation, approximately 80% of patients on dialysis reported trouble managing serum phosphorous levels.
Source: Getty Images
- In a recent press release, Ardelyx announced the results of a survey on dialysis patients in collaboration with the National Kidney Foundation. The survey revealed that the majority, 80%, of patients on dialysis struggle to manage serum phosphorous levels. An additional 90% of respondents explained a gap in treatment and hoped for new treatment options.
"Despite best efforts with current treatment strategies, a significant proportion of patients have persistent hyperphosphatemia, placing them at an increased risk for mineral and bone disorder complications, including vascular disease," said Joseph Vassalotti, MD, chief medical officer for the National Kidney Foundation in the press release. "These survey results point to the difficulty people living with kidney diseases treated with dialysis have coping with low phosphorus diet and current medication schedules."
According to the CDC, approximately 1 in 7 people in the United States suffer from chronic kidney disease. Additionally, the National Kidney Foundation states that nearly two million people worldwide undergo dialysis treatment. Of those on dialysis, approximately 745,000 people suffer from hyperphosphatemia. Hyperphosphatemia refers to elevated serum phosphorous levels.
The Ardelyx press release states that patients with hyperphosphatemia are currently prescribed phosphate binders to manage their serum phosphorous levels. However, these medications must be taken frequently, with multiple pills at each meal.
The survey results found that only 18% of patients maintained their serum phosphorous levels. Additionally, nearly 90% of respondents reported that it took an effort to manage phosphorous levels. The press release states, “88% reported at least some difficulty taking phosphate binders, with 60% reporting side effects from their phosphate binder pills, including nausea, diarrhea, constipation, and vomiting.”
Overall, the results of this survey display issues with the current management methods for hyperphosphatemia in patients undergoing dialysis. Future research methods may explore better ways to manage and monitor phosphorous levels. Until then, providers may consider providing additional support and resources to maintain serum phosphorous levels.
